Login to Your Account


Agencies push bug drug pipeline but development lacks market pull

By Marie Powers
News Editor

Wednesday, June 22, 2016

Efforts to improve the treatment of multidrug-resistant bacterial infections begin with the pipeline, and pipelines emerge from scientific prowess and dealmaking. Despite public rhetoric about confronting the superbug threat globally, experts contend that the cupboard of innovative treatments to address these pathogens is meager and the supply of scientists needed to restock the shelves is scarce.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription